Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
      Description

      This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).

      Conditions
      Part 1：r/r B-cell MalignanciesPart 2：B-cell Malignancies
      Talk to us
      COMPLETED
      Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
      Description

      This is a Phase 1, open-label, two-part, safety, PK, and activity study designed to characterize the DDI potential of tazemetostat. Tazemetostat will be taken orally BID continuously in 28-day cycles in both study parts.

      Conditions
      Diffuse Large B Cell LymphomaPrimary Mediastinal LymphomaMantle Cell LymphomaAdvanced Solid TumorMarginal Zone Lymphoma
      Talk to us